Basel, 17 December 2018 PRIME designation granted by European Medicines Agency for Roche’s risdiplam for treatment of spinal muscular atrophy (SMA) Risdiplam has the potential to be the first oral medicine for the treatment of SMA Types 1, 2 and 3; a rare and debilitating genetic disease most commonly diagnosed in children European Medicines Agency PRIME... Read more
Basel, 10 December 2018 New member proposed for election to Roche Board of Directors Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that at its December meeting the Board of Directors (BoD) of Roche Holding Ltd decided on first proposals for approval by the Annual General Meeting (AGM), scheduled for 5 March 2019. The BoD... Read more
Basel, 10 December 2018 Changes to the Roche Corporate Executive Committee Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Daniel O’Day, CEO Roche Pharmaceuticals and member of the Corporate Executive Committee, will be stepping down from his role as of 31 December 2018. Until the end of February 2019 and prior to assuming new... Read more
Basel, 07 December 2018 FDA approves Roche’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer Approval based on survival benefit of Tecentriq in combination with Avastin, paclitaxel and carboplatin (chemotherapy) in people with metastatic non-squamous non-small cell lung cancer (NSCLC) with no... Read more
Basel, 05 December 2018 Roche’s Kadcyla cut the risk of disease recurring by half compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment At three years, 88.3% of people treated with Kadcyla in the adjuvant HER2-positive early breast cancer setting did not have their breast cancer return compared... Read more
Basel, 05 December 2018 FDA grants priority review to Roche’s Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for... Read more
Basel, 04 December 2018 New Venclexta/Venclyxto data demonstrate deep responses in two of the most common types of leukaemia New analyses from the phase III MURANO study in previously treated chronic lymphocytic leukaemia show continued benefit from fixed-duration regimen after a median follow-up of three years Updated results from two studies in newly-diagnosed acute myeloid... Read more
Basel, 03 December 2018 Roche’s Hemlibra provided sustained bleed control in the largest pivotal study to date of children with haemophilia A with factor VIII inhibitors Nearly 77% of children receiving Hemlibra once weekly experienced zero treated bleeds Hemlibra once weekly reduced treated bleeds by 99% compared to prior bypassing agents in a prospective intra-patient... Read more
Basel, 03 December 2018 Longer-term follow-up data demonstrate sustained benefit of polatuzumab vedotin-based treatment in relapsed or refractory diffuse large B-cell lymphoma Polatuzumab vedotin in combination with MabThera/Rituxan (rituximab) plus bendamustine more than doubled overall survival, compared to MabThera/Rituxan plus bendamustine alone in the phase Ib/II GO29365 study Polatuzumab vedotin has the potential to provide... Read more
The VENTANA pan-TRK (EPR17341) Assay1 is the first assay of its type to detect tropomyosin receptor kinase (TRK) with anticipated use across multiple solid tumor types The assay is expected to provide improved data on the prevalence of TRK proteins in tumor tissue studies The significance of TRK fusion proteins is currently being investigated in various... Read more